DateNews item
2012Work starts to screen and optimize dietary bioactive compounds for induction of Glo1 expression – Healthy Aging Through Functional Food (HATFF or Hats-off) project.
2015PCT priority patent application file on Glo1 inducers.
2016Peer-reviewed publication on outcome of Healthy Aging Through Functional Food (HATFF or Hats-off) clinical trial study showing Glo1 inducer corrects insulin resistance and improves metabolic and vascular health in overweight and obese subjects.
Three presentations at 52nd Annual Meeting of the European Association For the Study of Diabetes (EASD), Munich, Germany on Glo1 inducer improvement of glycemic and vascular health. 
2017Presentation at the 69th American Association of Clinical Chemists Annual Scientific Meeting & Clinical Lab Expo, San Diego, USA, on protein glycation and Glo1 inducer therapeutics
Presentation at the American Diabetes Association 77th Scientific Sessions, San Diego, USA, on protein glycation and Glo1 inducer therapeutics
Presentation at the 53rd Annual Meeting of the European Association For the Study of Diabetes (EASD), Lisbon, Portugal, on protein glycation and Glo1 inducer therapeutics
2018Conference presentation on Glo1 inducer prevention of endothelial dysfunction in hyperglycemia at 54th Annual Meeting of the European Association For the Study of Diabetes (EASD), Berlin, Germany
2019Presentation at the 79th American Diabetes Association Scientific Sessions, San Francisco, USA, on Glo1 inducer correcting metabolic dysfunction in hyperglycemia 
Peer-reviewed publication on Glo1 inducer corrects endothelial cell dysfunction in model hyperglycemia.
2020Peer-reviewed publication on Glo1 inducer corrects fibroblast dysfunction in hyperglycemia.
2021Peer-reviewed publication on link of Glo1 inducer treatment to improvement of dysglycemia, blood pressure, dyslipidemia and low-grade inflammation in the HATFF study.
Presentation at the International Diabetes Federation Virtual Conference on Diabetic Complications on Glo1 inducer is a prospective new treatment for vascular complications of diabetes
2022Glocentrica Ltd takes ownership of Glo1 inducer patents in USA and Europe
2023European Patent Office grants patent on Glo1 inducer to Glocentrica Ltd
Peer-reviewed paper on how decreased methylglyoxal-modified protein is linked to healthy aging in a mouse model
2024Peer-reviewed paper on methylglyoxal and methylglyoxal-modified proteins are major physiological activators of the unfolded protein response (UPR), prevented by Glo1 inducer. 
Peer-reviewed paper on “Hexokinase-linked glycolytic overload and unscheduled glycolysis” explains how Glo1 inducer improves glycemic health”.
Peer-reviewed paper on “Unraveling the impaired incretin effect in obesity and type 2 diabetes: Key role of hyperglycemia-induced unscheduled glycolysis and glycolytic overload“, explaining how Glo1 inducer, GlucoRegulate, may be an adjunct or standalone after coming off therapy with GlP-1 agonists or GLP-1/GIP co-agonist such as Ozempic and Mournjaro.
2025Peer-reviewed paper on how GlucoRegulate supplement provides a new treatment option for the prevention of type 2 diabetes and prospectively also metabolic dysfunction–associated steatotic liver disease (MASLD) and supports healthy aging. “Glyoxalase 1 Inducer, trans-Resveratrol and Hesperetin–Dietary Supplement with Multi-Modal Health Benefit”
Peer-reviewed paper on how GlucoRegulate supplement may provide an emerging treatment for diabetic embryopathy “Overload of Glucose Metabolism as Initiating Factor in Diabetic Embryopathy and Prevention by Glyoxalase 1 Inducer Dietary Supplement“
Peer reviewed paper on the molecular mechanisms of metabolic dysfunction-associated steatotic liver disease (MASLD) – including GlucoRegulate offers a new approach to early-stage treatment “Molecular mechanisms of metabolic dysfunction-associated steatotic liver disease
(MASLD): functional analysis of glucose and fructose metabolism pathways“